

Leukaemia Section

Short Communication

t(1;22)(p13;q13)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers France (JLH)

Published in Atlas Database: June 2001

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0122.html>

DOI: 10.4267/2042/37759

This article is an update of:

Huret JL. t(1;22)(p13;q13). *Atlas Genet Cytogenet Oncol Haematol*.1999;3(4):193-194.

Huret JL. t(1;22)(p13;q13). *Atlas Genet Cytogenet Oncol Haematol*.1997;1(1):17.

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2001 *Atlas of Genetics and Cytogenetics in Oncology and Haematology*

Identity



t(1;22)(p13;q13) G- and R- banding

Clinics and pathology

Disease

Only found so far in M7 ANLL (acute megakaryocytic leukaemia); not found in Down syndrome (DS), and yet, DS is a disease with highly elevated risk of M7 (see leukaemia and Down Syndrome); misdiagnoses of a solid tumour have been documented.

Phenotype/cell stem origin

Megakaryocytic.

Etiology

No known toxic exposure.

Epidemiology

About 40 known cases; 0% to 3% of paediatric ANLL; 70 to 100% of infants M7; age: infants: median age 4 mths; 20% are < 1mth; 80% are < 1 yr; 95% are < 2 yrs; sex ratio: 15M/24F (non significant).

Clinics

No preceding myelodysplasia, and no history of transient leukemoid reaction; prominent organomegaly; blood data: moderate WBC; thrombocytopenia; myelofibrosis and fibrosis of other organs.

Cytology

Platelet-specific markers: platelet-peroxidase by electron microscopy, or platelet glycoproteins IIb/IIIa (CD41) or IIIa (CD61).

Treatment

Bone marrow transplantation is indicated.

Prognosis

Complete remission in only 50% of cases; median survival: 8 months; a few long survivors; absence of a prognostic indicator.

Cytogenetics

Additional anomalies

60% of cases (mostly patients under 6 mths of age) have the t(1;22) as a single anomaly; the remaining third of cases (mainly patients above the age of 6 mths) exhibit complex and hyperloid clones, with a highly monomorph pattern: +2, +19, +der(1)t(1;22), +6, +21 were found in more than 50% of cases each, +10, +7, +15, +18, +8, +20, del(1p), +4, +9, +14, +17, add(21p)

are also recurrent; survival was equivalent in cases with or without a complex karyotype; the frequent presence of an additional der(1) indicates that the crucial event is likely to lie on the der(1)t(1;22).

Variants

2 cases of complex t(1;22) with a third chromosome have been described.

Genes involved and proteins

OTT (one twenty-two)

Location: 1p13

Protein

Contains RNA recognition motif consensus.

MAL (megakaryocytic acute leukemia)

Location: 22q13

Protein

931 amino acids; could attach DNA to nuclear scaffold and be involved in chromatin organization

Result of the chromosomal anomaly

Hybrid gene

Description

5' OTT - 3' MAL, comprising most of OTT fused to most of MAL; the reciprocal 5' MAL - 3' OTT may or may not be present.

Fusion protein

Oncogenesis

May modulate chromatin organization, HOX differentiation pathways, or extracellular signalling.

To be noted

Note

Individual data on the 39 published cases of t(1;22) and a complete bibliography can be found in our t(1;22) study group page

References

Carroll A, Civin C, Schneider N, Dahl G, Pappo A, Bowman P, Emami A, Gross S, Alvarado C, Phillips C. The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. *Blood*. 1991 Aug 1;78(3):748-52

Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, Fink FM, Stojimirovic A, Herrmann J, Riehm HJ. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. *Blood*. 1992 Jun 15;79(12):3325-30

Lion T, Haas OA. Acute megakaryocytic leukemia with the t(1;22)(p13;q13). *Leuk Lymphoma*. 1993 Sep;11(1-2):15-20

Martinez-Climent JA, Lane NJ, Rubin CM, Morgan E, Johnstone HS, Mick R, Murphy SB, Vardiman JW, Larson RA, Le Beau MM. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. *Leukemia*. 1995 Jan;9(1):95-101

Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, Huret JL, Landman-Parker J, LeBeau MM, Leonard C, Mann G, Pages MP, Perot C, Pirc-Danoewinata H, Roitzheim B, Rubin CM, Slociak M, Viguie F. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. *Leukemia*. 2000 Jan;14(1):216-8

Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, Bouman D, Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GC, Chan LC, Squire J, Scherer SW, Hitzler JK. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. *Nat Genet*. 2001 Jul;28(3):220-1

Mercher T, Coniat MB, Monni R, Mauchauffe M, Nguyen Khac F, Gressin L, Mugneret F, Leblanc T, Dastugue N, Berger R, Bernard OA. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. *Proc Natl Acad Sci U S A*. 2001 May 8;98(10):5776-9

This article should be referenced as such:

Huret JL. t(1;22)(p13;q13). *Atlas Genet Cytogenet Oncol Haematol*. 2001; 5(3):193-194.
